EDP Biotech Preparing to Discuss Its Colon Cancer Dx with FDA | GenomeWeb

By Tony Fong

Following successful pre-clinical trials performed last year, EDP Biotech is preparing to submit its colorectal cancer diagnostic for regulatory approval with the US Food and Drug Administration.

The company plans to meet with the agency before the end of the first quarter to discuss the test, called ColoMarker, and then to begin a clinical trial in the hopes of getting FDA clearance in about three years, Kevin Jones, the company's chief scientific officer, told ProteoMonitor this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.